Publications by authors named "Birgit S Geurts"

Claim this Profile
C
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.
Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.
Ilse A C Spiekman, Niven Mehra, Laurien J Zeverijn, Birgit S Geurts, Karlijn Verkerk

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbial metabolic pathways guide response to immune checkpoint blockade therapy.
Iris L Mimpen, Thomas W Battaglia, Miguel Parra Martinez, Catherine Toner-Bartelds, Laurien J Zeverijn, Birgit S Geurts

Cancer Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, Jade M van Berge Henegouwen, Gijs F de Wit

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
Birgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, Jade M van Berge Henegouwen, Louisa R Hoes

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.
Jade M van Berge Henegouwen, Laurien J Zeverijn, Birgit S Geurts, Louisa R Hoes, Hanneke van der Wijngaart

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Birgit S Geurts, Laurien J Zeverijn, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, Louisa R Hoes

J Pathol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
Ilse A C Spiekman, Birgit S Geurts, Laurien J Zeverijn, Gijs F de Wit, Vincent van der Noort

Oncologist· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Ilse A C Spiekman, Laurien J Zeverijn, Birgit S Geurts, Karlijn Verkerk, Soemeya F Haj Mohammad

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).
Soemeya F Haj Mohammad, Hans J L Timmer, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman

Acta Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Karlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, Vincent van der Noort, Henk M W Verheul

Lancet Reg Health Eur· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pan-cancer analysis of the microbiome in metastatic cancer.
Thomas W Battaglia, Iris L Mimpen, Joleen J H Traets, Arne van Hoeck, Laurien J Zeverijn, Birgit S Geurts

Cell· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Laurien J Zeverijn, Eleonora J Looze, Subotheni Thavaneswaran, J Maxime van Berge Henegouwen, Robert J Simes, Birgit S Geurts

Int J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.
Tim Schutte, Laurien J Zeverijn, Birgit S Geurts, Gijsbrecht F de Wit, Marleen Kok

Oncologist· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Birgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, Laurien J Zeverijn, Gijs F de Wit

BMC Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
Natasja L de Vries, Joris van de Haar, Vivien Veninga, Myriam Chalabi, Marieke E Ijsselsteijn, Birgit S Geurts

Nature· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.
Laurien J Zeverijn, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Anke A M G Pisters van Roy, Lonneke Timmers, T H Ly Tran, Birgit S Geurts

Lancet Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis